AstraZeneca abandoning anti-ovarian cancer drug
LONDON - Drugmaker AstraZeneca PLC says it is abandoning plans to develop a new anti-ovarian cancer drug and also says a planned antidepressant has underperformed in tests.
AstraZeneca PLC on Monday reported a positive result in a Phase III study of its thyroid cancer drug.